Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae.
Magdalena Z PopielaRamez BarbaraAndrew M J TurnbullEmma CordenBeatriz Suarez Martinez-FaleroDaniel O'DriscollMichael R Ardern-JonesParwez N HossainPublished in: Eye (London, England) (2021)
The rate of dupilumab-associated ocular surface disease was 32%. Periorbital skin changes and conjunctival cicatrisation were noted in association with conjunctivitis. Ocular surface disease improved on topical steroids and ciclosporin but 67% of patients needed on-going treatment. Close liaison with an ophthalmologist should be considered in those patients who develop conjunctivitis or have a past history of severe ocular surface disease.